Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.

@article{HelwegLarsen2009ClinicalEO,
  title={Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.},
  author={Jannik Helweg-Larsen and Thomas Benfield and Chiara Atzori and Robert F Miller},
  journal={The Journal of antimicrobial chemotherapy},
  year={2009},
  volume={64 6},
  pages={
          1282-90
        }
}
OBJECTIVES First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients failing or developing toxicity to first-line therapy. METHODS A case note review of 1122 patients with 1188 episodes of HIV-associated PCP from three observational cohorts in Copenhagen, London and Milan, between 1989 and 2004, was conducted. RESULTS Trimethoprim/sulfamethoxazole (962 PCP episodes, 81%) was the most… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection.

  • Journal of immunology
  • 2015
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED